Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program

Under Mydecine’s recently announced Special Access Support and Supply Program, the Company will supply cGMP Psilocybin and MDMA to The Newly. The companies will partner to co-develop protocols, therapy manuals, and training needed to treat patients who need specific care. VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA)…

Source